CDK4 and breast cancer: Abemaciclib is already FDA-approved for HR+/HER2− breast cancer patients; hence, the future direction should involve testing the combination of abemaciclib with ICIs in patients with endometrial cancer as it has been proven that CDK4/6 inhibitors may promote antitumor immunity and may enhance the action of immune checkpoint inhibitors.